A study to evaluate the effects of a drug (propofol) in patients undergoing brain surgery for brain tumors
Phase 4
Recruiting
- Conditions
- Health Condition 1: null- Patients ,18-60 years of age, of either sex with intracranial space occupying lesion of ASA Grade I or II.
- Registration Number
- CTRI/2018/06/014411
- Lead Sponsor
- Dr Bhartesh Kumar Rai
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients of ASA Grade I or II.
2.Patients undergoing craniotomy and excision for space occupying lesions.
3.Expected duration of surgery is around 4-5 hours.
4.Patients with GCS 12 or above.
Exclusion Criteria
1.Patient not giving informed consent.
2.Hypersensitive to propofol.
3.Pregnancy, breastfeeding.
4.Children below 16 years.
5.Kidney or liver problems.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.BIS guided optimum dose of propofol for infusion intraoperatively. <br/ ><br>2.Haemodynamic stability of propofol infusion intraoperatively. <br/ ><br>3.Effects of propofol measured as reduced requirement of opioids and isoflurane intraoperatively. <br/ ><br>4.Level of postoperative sedation using Ramsay sedation score.Timepoint: 1.BIS guided optimum dose of propofol for infusion intraoperatively. <br/ ><br>2.Haemodynamic stability of propofol infusion intraoperatively. <br/ ><br>3.Effects of propofol measured as reduced requirement of opioids and isoflurane intraoperatively. <br/ ><br>4.Level of postoperative sedation using Ramsay sedation score.
- Secondary Outcome Measures
Name Time Method Any side effects intraoperatively.Timepoint: Any side effects intraoperatively.